TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT00424866: FGF-1 for Intramuscular Injection for the Treatment of Peripheral Arterial Disease

Sponsor: Venturis Therapeutics, Inc. · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 24 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$7,252,540

Rescue Site Savings

+$4,797,400

Unlock Full NCT00424866 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT00424866 Rescue Dossier →